Invivyd Inc. operates as a clinical-stage biopharmaceutical company dedicated to protecting vulnerable populations from serious viral infectious diseases through advanced engineered monoclonal antibody technologies. The enterprise focuses on leveraging proprietary platforms to discover, develop, and commercialize antibody-based therapies designed to provide rapid and long-lasting passive immunity against rapidly mutating pathogens such as SARS-CoV-2. Their overarching scientific objective is to bridge the gap between traditional vaccines and therapeutics by delivering reliable, alternative immune protection for immunocompromised and high-risk individuals worldwide.